J Hypertens:更佳血压和LDL水平对复发性卒中和认知障碍研究正在开展

2014-07-19 MedSci MedSci原创

以往有很多研究认为降低血压,以及降低LDL-C水平,可能能减少卒中的复发,以及减少认知障碍的发生。对于血压本身还存在争议,是否存在J型曲线一说。然而,血压与LDL-C相互作用,并不清楚。而且,最佳血压水平与LDL-C水平对卒中复发和认知障碍减少是否有更好的作用,这是值得研究的课题。一项全球多中心,随机对照,3x2析因设计的试验正在开展,试图解决这一难题。这项研究注册:NCT01563731。这

以往有很多研究认为降低血压,以及降低LDL-C水平,可能能减少卒中的复发,以及减少认知障碍的发生。对于血压本身还存在争议,是否存在J型曲线一说。然而,血压与LDL-C相互作用,并不清楚。而且,最佳血压水平与LDL-C水平对卒中复发和认知障碍减少是否有更好的作用,这是值得研究的课题。

一项全球多中心,随机对照,3x2析因设计的试验正在开展,试图解决这一难题。这项研究注册:NCT01563731。这项研究入选均为65岁以上老人,主要终点为卒中复发,次要终点为心血管事件,以及认知障碍的发生;计划招募7500名患者,研究预期2018年结束。研究分组包括SBP < 145-135 mmHg作为收缩压达标组,作为对照;以 SBP < 135-125 mmHg作为中等收缩压达标组;以 SBP < 125 mmHg为低收缩压达标组;另外,LDL-C 2.8 - 1.8 mmol/l 作为高LDL-C达标组;以LDL-C < 1.8 mmol/l 作为低LDL-C达标组;

原始出处:
Zanchetti A, Liu L, Mancia G, Parati G, Grassi G, Stramba-Badiale M, Silani V, Bilo G, Corrao G, Zambon A, Scotti L, Zhang X, Wang H, Zhang Y, Zhang X, Guan TR, Berge E, Redon J, Narkiewicz K, Dominiczak A, Nilsson P, Viigimaa M, Laurent S, Agabiti-Rosei E, Wu Z, Zhu D, Rodicio JL, Ruilope LM, Martell-Claros N, Pinto F, Schmieder RE, Burnier M, Banach M, Cifkova R, Farsang C, Konradi A, Lazareva I, Sirenko Y, Dorobantu M, Postadzhiyan A, Accetto R, Jelakovic B, Lovic D, Manolis AJ, Stylianou P, Erdine S, Dicker D, Wei G, Xu C, Xie H, Coca A, O'Brien J, Ford G.Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial.J Hypertens. 2014 Jun 27.

Zanchetti A, Liu L, Mancia G, Parati G, Grassi G, Stramba-Badiale M, Silani V, Bilo G, Corrao G, Zambon A, Scotti L, Zhang X, Wang H, Zhang Y, Zhang X, Guan TR, Berge E, Redon J, Narkiewicz K, Dominiczak A, Nilsson P, Viigimaa M, Laurent S, Agabiti-Rosei E, Wu Z, Zhu D, Rodicio JL, Ruilope LM, Martell-Claros N, Pinto F, Schmieder RE, Burnier M, Banach M, Cifkova R, Farsang C, Konradi A, Lazareva I, Sirenko Y, Dorobantu M, Postadzhiyan A, Accetto R, Jelakovic B, Lovic D, Manolis AJ, Stylianou P, Erdine S, Dicker D, Wei G, Xu C, Xie H, Coca A, O'Brien J, Ford G.Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence. J Hypertens. 2014 Jun 27. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1909556, encodeId=d079190955652, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Nov 03 04:46:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931373, encodeId=5a6219313e324, content=<a href='/topic/show?id=f34010e6985' target=_blank style='color:#2F92EE;'>#LDL水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10769, encryptionId=f34010e6985, topicName=LDL水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Tue Apr 14 15:46:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725639, encodeId=e6ec1e2563903, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Apr 20 20:46:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038493, encodeId=f68b2038493fd, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Sep 25 17:46:00 CST 2014, time=2014-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10559, encodeId=77af10559a7, content=这种研究分组很值得借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d2103784, createdName=chen111111, createdTime=Mon Jul 21 21:53:00 CST 2014, time=2014-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422518, encodeId=4c4214225184e, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Mon Jul 21 10:46:00 CST 2014, time=2014-07-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1909556, encodeId=d079190955652, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Nov 03 04:46:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931373, encodeId=5a6219313e324, content=<a href='/topic/show?id=f34010e6985' target=_blank style='color:#2F92EE;'>#LDL水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10769, encryptionId=f34010e6985, topicName=LDL水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Tue Apr 14 15:46:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725639, encodeId=e6ec1e2563903, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Apr 20 20:46:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038493, encodeId=f68b2038493fd, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Sep 25 17:46:00 CST 2014, time=2014-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10559, encodeId=77af10559a7, content=这种研究分组很值得借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d2103784, createdName=chen111111, createdTime=Mon Jul 21 21:53:00 CST 2014, time=2014-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422518, encodeId=4c4214225184e, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Mon Jul 21 10:46:00 CST 2014, time=2014-07-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1909556, encodeId=d079190955652, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Nov 03 04:46:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931373, encodeId=5a6219313e324, content=<a href='/topic/show?id=f34010e6985' target=_blank style='color:#2F92EE;'>#LDL水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10769, encryptionId=f34010e6985, topicName=LDL水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Tue Apr 14 15:46:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725639, encodeId=e6ec1e2563903, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Apr 20 20:46:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038493, encodeId=f68b2038493fd, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Sep 25 17:46:00 CST 2014, time=2014-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10559, encodeId=77af10559a7, content=这种研究分组很值得借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d2103784, createdName=chen111111, createdTime=Mon Jul 21 21:53:00 CST 2014, time=2014-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422518, encodeId=4c4214225184e, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Mon Jul 21 10:46:00 CST 2014, time=2014-07-21, status=1, ipAttribution=)]
    2015-04-20 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1909556, encodeId=d079190955652, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Nov 03 04:46:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931373, encodeId=5a6219313e324, content=<a href='/topic/show?id=f34010e6985' target=_blank style='color:#2F92EE;'>#LDL水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10769, encryptionId=f34010e6985, topicName=LDL水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Tue Apr 14 15:46:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725639, encodeId=e6ec1e2563903, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Apr 20 20:46:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038493, encodeId=f68b2038493fd, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Sep 25 17:46:00 CST 2014, time=2014-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10559, encodeId=77af10559a7, content=这种研究分组很值得借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d2103784, createdName=chen111111, createdTime=Mon Jul 21 21:53:00 CST 2014, time=2014-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422518, encodeId=4c4214225184e, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Mon Jul 21 10:46:00 CST 2014, time=2014-07-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1909556, encodeId=d079190955652, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Nov 03 04:46:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931373, encodeId=5a6219313e324, content=<a href='/topic/show?id=f34010e6985' target=_blank style='color:#2F92EE;'>#LDL水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10769, encryptionId=f34010e6985, topicName=LDL水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Tue Apr 14 15:46:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725639, encodeId=e6ec1e2563903, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Apr 20 20:46:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038493, encodeId=f68b2038493fd, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Sep 25 17:46:00 CST 2014, time=2014-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10559, encodeId=77af10559a7, content=这种研究分组很值得借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d2103784, createdName=chen111111, createdTime=Mon Jul 21 21:53:00 CST 2014, time=2014-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422518, encodeId=4c4214225184e, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Mon Jul 21 10:46:00 CST 2014, time=2014-07-21, status=1, ipAttribution=)]
    2014-07-21 chen111111

    这种研究分组很值得借鉴

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1909556, encodeId=d079190955652, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Nov 03 04:46:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931373, encodeId=5a6219313e324, content=<a href='/topic/show?id=f34010e6985' target=_blank style='color:#2F92EE;'>#LDL水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10769, encryptionId=f34010e6985, topicName=LDL水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Tue Apr 14 15:46:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725639, encodeId=e6ec1e2563903, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Apr 20 20:46:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038493, encodeId=f68b2038493fd, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Sep 25 17:46:00 CST 2014, time=2014-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10559, encodeId=77af10559a7, content=这种研究分组很值得借鉴, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d2103784, createdName=chen111111, createdTime=Mon Jul 21 21:53:00 CST 2014, time=2014-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422518, encodeId=4c4214225184e, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Mon Jul 21 10:46:00 CST 2014, time=2014-07-21, status=1, ipAttribution=)]
    2014-07-21 zhwj

相关资讯

JAMA述评:新胆固醇与血压指南——前景展望

作者:哈伦•M•克鲁姆霍尔茨(美国纽黑文市耶鲁大学医学院内科学系心血管医学部)经历了很久的延迟、审议与冲突之后,大家期待已久的更新版胆固醇与血压指南在过去的6个月期间发布了。上几个版本的权威文件发布已有十多年,更新版指南是要提炼出此后出现的智慧成果。2008年,美国国立卫生研究院(NIH)委派了一些美国顶级专家到各个委员会,并在几乎整个5年的发展中提供指导。这些文件旨在为美国和全世界就如何管理

ESH 2014:老年人群中血压与死亡风险的关系及生物学年龄在其中的关键作用

目前,在老年人群中高血压对死亡率的预测价值尚存争议。有数据表明,在某些特定的老年亚组人群中,两者的关系会倒置。ESH大会上,荷兰列登大学医学中心M. Muller发表一项研究,评估患者的实际年龄以及反映生物学年龄的身体及认知功能是否会影响血压与死亡率的相关性。 研究入选LASA研究中的1466例年龄≥65岁的受试者(平均年龄为76岁),采用多因素校正Cox比例风险模型评估血压与全因死亡率的相关性

PNAS:地中海式饮食有助降血压

果蔬沙拉加橄榄油是十分健康的搭配。一个国际研究小组最新发现,这种地中海式饮食在降血压、保护心血管健康方面的益处确有科学依据。研究报告发表在美国新一期《国家科学院学报》上。地中海地区的居民多喜欢食用水果、蔬菜、坚果和谷类等,食用油则以橄榄油和菜油为主。此前研究发现,这种饮食习惯对心血管健康大有裨益。英国伦敦大学国王学院研究人员与欧洲同行一起报告说,他们通过动物实验发现,橄榄油、坚果中富含

JAMA:脑卒中急性期的血压控制

血压升高在缺血性脑卒中患者中很常见。脑缺血早期如何进行高血压的管理,目前仍是一个亟待解决的问题。一方面血压适度控制可以减轻脑水肿,阻止脑梗死向脑出血转换,有助于防止并发心肌损伤。另一方面,早期血压降低可能减少侧支血流灌注,使梗死范围扩大。【原文下载】因此,需要大量的临床试验,以确定脑卒中早期血压管理的最佳方案,而此前的试验提供的指导均不完整。近几年,2个大型试验(COSSACS、SCAST)进一步

Diabetes Care:痛性糖尿病神经病变与“非杓型”血压相关

新近一项研究发现,痛性糖尿病多发性神经病(PDPN)与夜间血压(BP)增高有关,这种相关性独立于疼痛相关的共患病。相关研究结果由来自意大利罗马第二大学的Cinzia D'Amato及其同事于6月26日在线发表于《糖尿病护理(Diabetes Care)》杂志。 研究负责人Vincenza Spallone, MD说:“PDPN是一种常见并发症,可对睡眠、情绪和生活质量产生极大影响。但该病通常未能

Lancet:收缩压和舒张压可预测不同的心血管疾病风险

根据已在柳叶刀发表的一项来自英格兰最新的特殊调查报告所示,升高的收缩压和舒张压可能对不同类型的心血管疾病起着不同的作用,该结论基于 CALIBER (CArdiovascular research using LInked Bespoke studies and Electronic health Records) 计划中125万30岁以上患者的统计数据得出。 这项新发现表明具有较高收缩压